Weight Loss & GLP-1 Peptides

The GLP-1 Revolution in Weight Management

GLP-1 (glucagon-like peptide-1) receptor agonists have fundamentally changed the landscape of obesity treatment. Originally developed for type 2 diabetes, these peptides mimic the incretin hormones your body naturally produces after eating — reducing appetite, slowing gastric emptying, and improving insulin sensitivity. The result is sustained, clinically meaningful weight loss that was previously achievable only through bariatric surgery.

As of 2026, three compounds dominate the conversation: semaglutide (the active ingredient in Ozempic and Wegovy), tirzepatide (Mounjaro/Zepbound), and the investigational triple agonist retatrutide. Each represents a different generation of the technology, with progressively more powerful metabolic effects.

Semaglutide — The First Breakthrough

Semaglutide was the compound that launched the modern weight loss peptide era. As a selective GLP-1 receptor agonist, it activates a single metabolic pathway — but does so with remarkable potency. The STEP clinical trial program demonstrated mean weight loss of approximately 15% of body weight over 68 weeks at the 2.4mg weekly dose.

Semaglutide works by binding to GLP-1 receptors in the hypothalamus (reducing appetite and food reward signaling), the pancreas (enhancing insulin secretion), and the gastrointestinal tract (slowing gastric emptying, which increases satiety). Its albumin-binding fatty acid sidechain gives it a half-life of approximately 7 days, enabling once-weekly dosing.

• Clinical weight loss: ~15% body weight reduction over 68 weeks (STEP trials)
• Cardiovascular benefit: SELECT trial showed 20% reduction in major adverse cardiovascular events
• Dosing: Weekly subcutaneous injection, dose escalation from 0.25mg to 2.4mg over 16-20 weeks
• FDA status: Approved as Wegovy (weight management) and Ozempic (type 2 diabetes)

Tirzepatide — The Dual Agonist Leap

Tirzepatide took the approach further by activating two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism produces additive metabolic effects — GIP receptor activation appears to enhance fat metabolism and improve the insulin response beyond what GLP-1 alone achieves.

The SURMOUNT trial program showed tirzepatide producing weight loss of up to 22.5% at the highest dose (15mg) — a significant improvement over semaglutide's results and approaching outcomes historically seen only with surgical interventions.

• Clinical weight loss: Up to 22.5% body weight reduction at 15mg over 72 weeks (SURMOUNT-1)
• Dual mechanism: GLP-1 + GIP receptor agonism creates synergistic metabolic effects
• Metabolic improvements: Superior HbA1c reduction and insulin sensitization compared to semaglutide
• FDA status: Approved as Mounjaro (T2D) and Zepbound (weight management)

Retatrutide — The Triple Agonist Frontier

Retatrutide represents the next evolutionary step: a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor activation increases energy expenditure and hepatic fat oxidation — addressing obesity from the energy output side as well as the appetite suppression side.

Phase II trial data showed unprecedented results: up to 24.2% body weight reduction at the highest dose over 48 weeks. Eli Lilly's Phase III TRIUMPH program is currently enrolling, and if results hold, retatrutide could redefine the ceiling of pharmacological weight loss.

• Clinical weight loss: Up to 24.2% at 12mg/48 weeks in Phase II — exceeding both semaglutide and tirzepatide
• Triple mechanism: GLP-1 + GIP + glucagon receptor agonism
• Liver fat: Dramatic reductions in hepatic steatosis, potentially transformative for NAFLD/NASH
• Status: Investigational — Phase III trials ongoing, not yet FDA-approved

Side Effects & What to Expect

All GLP-1 agonists share a common side effect profile dominated by gastrointestinal effects: nausea, vomiting, diarrhea, and constipation. These are most pronounced during dose escalation and generally improve over 4-8 weeks. Slow, gradual dose titration is the primary strategy for minimizing these effects.

Other considerations include potential for muscle mass loss alongside fat loss (resistance training during treatment is strongly recommended), gallbladder issues at higher doses, and the psychological adjustment to fundamentally altered appetite and food relationships.

How to Access GLP-1 Peptides Legally

FDA-approved semaglutide and tirzepatide are available through licensed healthcare providers via prescription. Many telehealth platforms now specialize in GLP-1 prescribing. Research-grade compounds are available from verified suppliers for laboratory use — always verify third-party COAs and supplier reputation before purchasing.

Related Peptide Profiles